SeaLife’s screening platform is based on 3 pillars: bacterial, fungal and viral testing. More than 100 different clinically relevant bacteria and fungi strains, six different groups of viruses and a strong focus on skin and respiratory tract infections puts SeaLife in the position to screen substances in nearly all relevant indications. The platform is compliant to EUCAST (European Committee for Antimicrobial Susceptibility Testing) and AFST (Antifungal Susceptibility Testing) standards based on the European Society of Clinical Microbiology and Infectious Diseases (ESCMID).
Screening platform reflects today's needs
With a high-throughput system, detailed reporting and strong focus on quality management during the screening process, SeaLife identifies potential drug candidates very efficiently.
